{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:47:36Z","timestamp":1782380856213,"version":"3.54.5"},"reference-count":47,"publisher":"China Science Publishing & Media Ltd.","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.3724\/abbs.2026084","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:26:39Z","timestamp":1778642799000},"update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["HDAC6 promotes osimertinib resistance evolution in non-small cell lung cancer by activating EGFR degradation through the ubiquitin-proteasome pathway"],"prefix":"10.3724","author":[{"given":"Cheng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danlei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangkang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74: 229-263.","journal-title":"CA Cancer J Clin"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"Leiter A","year":"2023","unstructured":"Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol, 2023, 20: 624-639.","journal-title":"Nat Rev Clin Oncol"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1126\/science.1073096","volume":"297","author":"Weinstein IB","year":"2002","unstructured":"Weinstein IB. Addiction to oncogenes\u2014the achilles heal of cancer. Science, 2002, 297: 63-64.","journal-title":"Science"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"Lynch TJ","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350: 2129-2139.","journal-title":"N Engl J Med"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"Cross DAE","year":"2014","unstructured":"Cross DAE, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov, 2014, 4: 1046-1061.","journal-title":"Cancer Discov"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"Mok TS","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA. Osimertinib or platinum-pemetrexed in                         EGFR T790M-positive lung cancer. N Engl J Med, 2017, 376: 629-640.","journal-title":"N Engl J Med"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"Ramalingam SS","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C. Overall survival with osimertinib in untreated,                         EGFR-mutated advanced NSCLC. N Engl J Med, 2020, 382: 41-50.","journal-title":"N Engl J Med"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1097\/JTO.0000000000000688","volume":"10","author":"Kim TM","year":"2015","unstructured":"Kim TM, Song A, Kim DW, Kim S, Ahn YO, Keam B, Jeon YK. Mechanisms of acquired resistance to AZD9291. J Thoracic Oncol, 2015, 10: 1736-1744.","journal-title":"J Thoracic Oncol"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","volume":"17","author":"Oxnard GR","year":"2011","unstructured":"Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res, 2011, 17: 1616-1622.","journal-title":"Clin Cancer Res"},{"key":"CITATION10","unstructured":"Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells                         in vitro: cross-resistance, radioautographic, and cytogenetic studies.                                                      Cancer Res                          1970, 30: 1174\u20131184."},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fonc.2014.00040","volume":"4","author":"McDermott M","year":"2014","unstructured":"McDermott M, Eustace AJ, Busschots S, Breen L, Crown J, Clynes M, O\u2032Donovan N. In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. Front Oncol, 2014, 4: 40.","journal-title":"Front Oncol"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1158\/0008-5472.CAN-19-0729","volume":"80","author":"Finn KJ","year":"2020","unstructured":"Finn KJ, Martin SE, Settleman J. A single-step, high-dose selection scheme reveals distinct mechanisms of acquired resistance to oncogenic kinase inhibition in cancer cells. Cancer Res, 2020, 80: 79-90.","journal-title":"Cancer Res"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jtho.2019.11.005","volume":"15","author":"Schoenfeld AJ","year":"2020","unstructured":"Schoenfeld AJ, Yu HA. The evolving landscape of resistance to osimertinib. J Thoracic Oncol, 2020, 15: 18-21.","journal-title":"J Thoracic Oncol"},{"key":"CITATION14","doi-asserted-by":"crossref","unstructured":"Zhang L, Lu Q, Chang C. Epigenetics in health and disease.                                                      Adv Exp Med Biol                          2020, 1253: 3\u201355.","DOI":"10.1007\/978-981-15-3449-2_1"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41580-021-00441-y","volume":"23","author":"Shvedunova M","year":"2022","unstructured":"Shvedunova M, Akhtar A. Modulation of cellular processes by histone and non-histone protein acetylation. Nat Rev Mol Cell Biol, 2022, 23: 329-349.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrg2485","volume":"10","author":"Haberland M","year":"2009","unstructured":"Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet, 2009, 10: 32-42.","journal-title":"Nat Rev Genet"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","volume":"8","author":"Wang N","year":"2023","unstructured":"Wang N, Ma T, Yu B. Targeting epigenetic regulators to overcome drug resistance in cancers. Sig Transduct Target Ther, 2023, 8: 69.","journal-title":"Sig Transduct Target Ther"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1158\/0008-5472.CAN-19-3738","volume":"80","author":"Banik D","year":"2020","unstructured":"Banik D, Noonepalle S, Hadley M, Palmer E, Gracia-Hernandez M, Zevallos-Delgado C, Manhas N. HDAC6 plays a noncanonical role in the regulation of antitumor immune responses, dissemination, and invasiveness of breast cancer. Cancer Res, 2020, 80: 3649-3662.","journal-title":"Cancer Res"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.3390\/cancers12123734","volume":"12","author":"Ali A","year":"2020","unstructured":"Ali A, Zhang F, Maguire A, Byrne T, Weiner-Gorzel K, Bridgett S, O\u2019Toole S. HDAC6 degradation inhibits the growth of high-grade serous ovarian cancer cells. Cancers, 2020, 12: 3734.","journal-title":"Cancers"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41388-023-02641-6","volume":"42","author":"Liu B","year":"2023","unstructured":"Liu B, Zhang J, Meng X, Xie SM, Liu F, Chen H, Yao D. HDAC6-G3BP2 promotes lysosomal-TSC2 and suppresses mTORC1 under ETV4 targeting-induced low-lactate stress in non-small cell lung cancer. Oncogene, 2023, 42: 1181-1195.","journal-title":"Oncogene"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","volume":"13","author":"Liang T","year":"2023","unstructured":"Liang T, Wang F, Elhassan RM, Cheng Y, Tang X, Chen W, Fang H. Targeting histone deacetylases for cancer therapy: trends and challenges. Acta Pharm Sin B, 2023, 13: 2425-2463.","journal-title":"Acta Pharm Sin B"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.7150\/ijbs.18834","volume":"13","author":"Yu S","year":"2017","unstructured":"Yu S, Cai X, Wu C, Liu Y, Zhang J, Gong X, Wang X. Targeting HSP90-HDAC6 regulating network implicates precision treatment of breast cancer. Int J Biol Sci, 2017, 13: 505-517.","journal-title":"Int J Biol Sci"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"e44265","DOI":"10.1371\/journal.pone.0044265","volume":"7","author":"Wang L","year":"2012","unstructured":"Wang L, Xiang S, Williams KA, Dong H, Bai W, Nicosia SV, Khochbin S. Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. PLoS One, 2012, 7: e44265.","journal-title":"PLoS One"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/neuonc\/noaa103","volume":"22","author":"Yang WB","year":"2020","unstructured":"Yang WB, Hsu CC, Hsu TI, Liou JP, Chang KY, Chen PY, Liu JJ. Increased activation of HDAC1\/2\/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma. Neuro-Oncology, 2020, 22: 1439-1451.","journal-title":"Neuro-Oncology"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41419-020-2519-8","volume":"11","author":"Hu C","year":"2020","unstructured":"Hu C, Zhang M, Moses N, Hu C, Polin L, Chen W, Jang H. The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53. Cell Death Dis, 2020, 11: 328.","journal-title":"Cell Death Dis"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12032-016-0765-5","volume":"33","author":"Wang Z","year":"2016","unstructured":"Wang Z, Hu P, Tang F, Xie C. HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells. Med Oncol, 2016, 33: 50.","journal-title":"Med Oncol"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3892\/or.2016.4811","volume":"36","author":"Wang Z","year":"2016","unstructured":"Wang Z, Tang F, Hu P, Wang Y, Gong J, Sun S, Xie C. HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. Oncol Rep, 2016, 36: 589-597.","journal-title":"Oncol Rep"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"5396","DOI":"10.1074\/jbc.M115.713123","volume":"291","author":"Gu S","year":"2016","unstructured":"Gu S, Liu Y, Zhu B, Ding K, Yao TP, Chen F, Zhan L. Loss of \u03b1-tubulin acetylation is associated with TGF-\u03b2-induced epithelial-mesenchymal transition. J Biol Chem, 2016, 291: 5396-5405.","journal-title":"J Biol Chem"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"102557","DOI":"10.1016\/j.ctrv.2023.102557","volume":"116","author":"Zalaquett Z","year":"2023","unstructured":"Zalaquett Z, Catherine Rita Hachem M, Kassis Y, Hachem S, Eid R, Raphael Kourie H, Planchard D. Acquired resistance mechanisms to osimertinib: the constant battle. Cancer Treat Rev, 2023, 116: 102557.","journal-title":"Cancer Treat Rev"},{"key":"CITATION30","first-page":"725","volume":"121","author":"Leonetti A","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer, 2019, 121: 725-737.","journal-title":"Br J Cancer"},{"key":"CITATION31","unstructured":"Zhu Z, Sun L, Li X, Xu X. Research progress on resistance mechanisms and therapeutic strategies against osimertinib in non-small cell lung cancer.                                                      Cancer Research and Clinic                          2023, 35: 717-720."},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12964-023-01260-8","volume":"22","author":"Ding X","year":"2024","unstructured":"Ding X, Shi M, Liu D, Cao J, Zhang K, Zhang R, Zhang L. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer. Cell Commun Signal, 2024, 22: 45.","journal-title":"Cell Commun Signal"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"100845","DOI":"10.1016\/j.neo.2022.100845","volume":"35","author":"Dai HY","year":"2023","unstructured":"Dai HY, Chang LS, Yang SF, Wang SN, Su SJ, Yeh YT. HDAC6 promotes aggressive development of liver cancer by improving EGFR mRNA stability. Neoplasia, 2023, 35: 100845.","journal-title":"Neoplasia"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","volume":"4","author":"Oxnard GR","year":"2018","unstructured":"Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N. Assessment of resistance mechanisms and clinical implications in patients with                         EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol, 2018, 4: 1527-1534.","journal-title":"JAMA Oncol"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"102664","DOI":"10.1016\/j.ctrv.2023.102664","volume":"122","author":"Ciardiello F","year":"2024","unstructured":"Ciardiello F, Hirsch FR, Pirker R, Felip E, Valencia C, Smit EF. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer. Cancer Treat Rev, 2024, 122: 102664.","journal-title":"Cancer Treat Rev"},{"key":"CITATION36","doi-asserted-by":"publisher","first-page":"117218","DOI":"10.1016\/j.biopha.2024.117218","volume":"178","author":"Huang Z","year":"2024","unstructured":"Huang Z, Li L, Cheng B, Li D. Small molecules targeting HDAC6 for cancer treatment: current progress and novel strategies. Biomed Pharmacother, 2024, 178: 117218.","journal-title":"Biomed Pharmacother"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41467-024-55378-5","volume":"16","author":"Alsaed B","year":"2025","unstructured":"Alsaed B, Lin L, Son J, Li J, Smolander J, Lopez T, Eser P\u00d6. Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment. Nat Commun, 2025, 16: 28.","journal-title":"Nat Commun"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"e41017","DOI":"10.1371\/journal.pone.0041017","volume":"7","author":"Shellman YG","year":"2012","unstructured":"Shellman YG, Tabara K, Kanda R, Sonoda K, Kubo T, Murakami Y, Kawahara A, Azuma K. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PLoS One, 2012, 7: e41017.","journal-title":"PLoS One"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"8035","DOI":"10.1128\/MCB.21.23.8035-8044.2001","volume":"21","author":"Seigneurin-Berny D","year":"2001","unstructured":"Seigneurin-Berny D, Verdel A, Curtet S, Lemercier C, Garin J, Rousseaux S, Khochbin S. Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways. Mol Cell Biol, 2001, 21: 8035-8044.","journal-title":"Mol Cell Biol"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"114438","DOI":"10.1016\/j.biopha.2023.114438","volume":"161","author":"Zhu Y","year":"2023","unstructured":"Zhu Y, Feng M, Wang B, Zheng Y, Jiang D, Zhao L, Mamun MAA. New insights into the non-enzymatic function of HDAC6. Biomed Pharmacother, 2023, 161: 114438.","journal-title":"Biomed Pharmacother"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molcel.2014.04.028","volume":"55","author":"Zhang M","year":"2014","unstructured":"Zhang M, Xiang S, Joo HY, Wang L, Williams KA, Liu W, Hu C. HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of MutS\u03b1. Mol Cell, 2014, 55: 31-46.","journal-title":"Mol Cell"},{"key":"CITATION42","doi-asserted-by":"publisher","first-page":"ra84","DOI":"10.1126\/scisignal.2000576","volume":"2","author":"Deribe YL","year":"2009","unstructured":"Deribe YL, Wild P, Chandrashaker A, Curak J, Schmidt MHH, Kalaidzidis Y, Milutinovic N. Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Sci Signal, 2009, 2: ra84.","journal-title":"Sci Signal"},{"key":"CITATION43","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s12272-021-01359-x","volume":"44","author":"Park SJ","year":"2021","unstructured":"Park SJ, Joo SH, Lee N, Jang WJ, Seo JH, Jeong CH. ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy. Arch Pharm Res, 2021, 44: 1062-1075.","journal-title":"Arch Pharm Res"},{"key":"CITATION44","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1002\/cncr.32744","volume":"126","author":"Zang H","year":"2020","unstructured":"Zang H, Qian G, Zong D, Fan S, Owonikoko TK, Ramalingam SS, Sun SY. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). Cancer, 2020, 126: 2024-2033.","journal-title":"Cancer"},{"key":"CITATION45","doi-asserted-by":"publisher","first-page":"907981","DOI":"10.3389\/fphar.2022.907981","volume":"13","author":"Li J","year":"2022","unstructured":"Li J, Yu M, Fu S, Liu D, Tan Y. Role of selective histone deacetylase 6 inhibitor ACY-1215 in cancer and other human diseases. Front Pharmacol, 2022, 13: 907981.","journal-title":"Front Pharmacol"},{"key":"CITATION46","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1158\/1078-0432.CCR-21-0238","volume":"27","author":"Tsimberidou AM","year":"2021","unstructured":"Tsimberidou AM, Beer PA, Cartwright CA, Haymaker C, Vo HH, Kiany S, Cecil ARL. Preclinical development and first-in-human study of KA2507, a selective and potent inhibitor of histone deacetylase 6, for patients with refractory solid tumors. Clin Cancer Res, 2021, 27: 3584-3594.","journal-title":"Clin Cancer Res"},{"key":"CITATION47","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1080\/07853890.2022.2045347","volume":"54","author":"Zhu Z","year":"2022","unstructured":"Zhu Z, Wen J, Xu Y, Pei H, Li D, Tang M, Bai P. Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model. Ann Med, 2022, 54: 743-753.","journal-title":"Ann Med"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/E3431ECA8A34480BB3EAA2F5919EF117","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2026084","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/E3431ECA8A34480BB3EAA2F5919EF117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:07:44Z","timestamp":1782378464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2026084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":47,"URL":"https:\/\/doi.org\/10.3724\/abbs.2026084","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}